-
Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline
•
Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly raised over RMB 100 million (USD 13.9 million) in a new financing round. The round was led by GTJA Investment, marking a significant capital injection into the company’s pipeline development. Company Background and Product PipelineFounded…
-
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
•
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products Administration (NMPA) in China to conduct an open, multi-center Phase II dose-setting study. The study will assess the efficacy and safety of BI 764532 in patients with recurrent/refractory extensive-stage small cell lung cancer (ES-SCLC) and…
-
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
•
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug Administration (WFDA) to conduct a multi-region, multi-center clinical study for its innovative fusion protein, HCB101. HCB101: A Promising Fusion Protein for Cancer TreatmentHCB101 is an engineered SIRP linked to IgG4-Fc α fusion proteins that can…
-
Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal
•
Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired the South Korea and Japan-based units of Swiss firm Idorsia Ltd (SWX: IDIA) for a purchase price of approximately JPY 65 billion (USD 460 million), to be paid in cash. Expanding Sosei’s Portfolio in Asia-PacificThe…
-
InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study
•
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its second-generation pan-TRK inhibitor, ICP-723, in pediatric patients aged 2 to 12 years. This follows…
-
Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease
•
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported receiving European Commission (EC) approval for Jardiance (empagliflozin) as a treatment for adults with chronic kidney disease (CKD). This marks an expansion of Jardiance’s indications, which already include type 2 diabetes and heart failure. Expanding…
-
Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts
•
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter of 2023, which shows the firm continuing to face challenges due to the underwhelming market entry of its Alzheimer’s therapy, Aduhelm (aducanumab). In response, Biogen announced plans to make 1,000 job cuts as part of…
-
FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment
•
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO: 4568) for its type II FLT3 inhibitor, Vanflyta (quizartinib), as a maintenance treatment following consolidation chemotherapy for newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive in adult patients. Phase III Study Results and…
